Emerging retatrutide, a dual -action treatment targeting simultaneously GLP-1 and GIP receptors, is creating considerable buzz within the weight loss community. Early clinical research have revealed impressive decreases in physical weight and gains in health markers for patients with obesity . Researchers believe this ground-breaking approach could